{"success":true,"data":{"pressRelease":{"id":"129780","rtpr_id":"nPNAzMDNza","ticker":"KZIA","exchange":"NASDAQ","all_tickers":["KZIA"],"title":"Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer","author":"PR Newswire","published_at":"2026-08-27T20:01:00.638Z","article_body":"Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients\nTreated for Advanced Triple-Negative Breast Cancer\nPR Newswire\n\nSYDNEY, Aug. 28, 2026\n\nDurable Complete Metabolic Response Ongoing Since November 2025\n\nAll Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC\nClusters and Terminally Exhausted T cells, With Median Reductions of 83% and\n51% Respectively\n\nNo Treatment-Related Serious Adverse Events Observed\n\nSYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4761405-1&h=3234957468&u=https%3A%2F%2Fwww.kaziatherapeutics.com%2F&a=Kazia+Therapeutics+Limited) (NASDAQ:\nKZIA) (\"Kazia\" or the \"Company\"), an oncology-focused biotechnology company\ndeveloping therapies that selectively reprogram cancer biology, restore\nanti-tumor immunity and overcome treatment resistance, today announced new\ndata showing its lead asset, paxalisib, achieved a 100% clinical benefit rate\nin six evaluable patients with Stage IV triple-negative breast cancer (TNBC).\nFive of the six patients achieved an objective response – a measurable 30%\nor greater reduction in tumor burden after treatment – including one\ncomplete response and four partial responses, resulting in an objective\nresponse rate of 83 percent. The remaining patient achieved stable disease.\nImportantly, these results were achieved with the convenience of oral dosing\nand a favorable safety and tolerability profile, with no paxalisib-related\nserious adverse events and no grade 3 or higher hyperglycemia, stomatitis or\nmucositis, toxicities commonly associated with PI3K/mTOR pathway inhibition.\n\n\n\n\"Metastatic triple-negative breast cancer is one of the toughest cancers to\ntreat. Historically, only 12 percent\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4761405-1&h=21108310&u=https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fbreast%2Fbreast-cancer-types%2Ftriple-negative&a=12+percent) of\npatients are alive five years after diagnosis. Once a patient's disease\nprogresses on immunotherapy, options run out quickly,\" said Dr. John Friend,\nCEO, Kazia Therapeutics. \"Across the six evaluable patients treated, every one\nof them has benefited, and we haven't seen a single serious adverse event tied\nto paxalisib. We've also demonstrated meaningful improvements in terminally\nexhausted T cells and drastic reductions in circulating tumor cell (CTC)\nclusters, providing early evidence that paxalisib may be addressing biological\nmechanisms associated with treatment resistance and metastasis. These results\nstrengthen our confidence in this program as we continue enrollment in the\nPhase 1b trial.\"\n\nClinical responses were observed across a broad range of metastatic disease\nsites, including lung, liver, bone, lymph node and central nervous system\ntarget lesions, with responses emerging as early as approximately three months\npost-randomization. Most notably, a 44-year-old woman with Stage IV TNBC\nachieved a complete metabolic response and has had no evidence of disease\nsince November 2025. Her response has remained durable through the most recent\nassessment and has been accompanied by sustained and complete abolishment of\nCTC clusters and significant reduction in terminally exhausted CD8+ T cells,\nalongside overall improvement in markers of immune function.\n\nTranslational analyses demonstrated reductions in terminally exhausted CD8+ T\ncells across all six patients, with a median reduction of 51 percent within\napproximately three weeks of treatment. These cells represent a dysfunctional\npopulation of cytotoxic T cells that has lost its ability to recognize and\nkill cancer cells. Notably, total CD8+ T cell counts remained unchanged, which\nsuggests that paxalisib is not eliminating these exhausted cells or replacing\nthem with new ones. Instead, the existing cells appear to be regaining\nfunction. Blood-based simultaneous multi-modal protein, RNA and plasma\nprofiling supported this finding, demonstrating increases in immune cell\npopulations associated with anti-tumor activity, reductions in markers of\nimmune exhaustion and evidence of PI3K-AKT pathway target engagement. The\nmarker findings provide evidence of improved overall immune function across\nall patients.\n\nIn parallel with the immune changes, all six patients demonstrated reductions\nin circulating tumor cell clusters, which are aggressive groupings of tumor\ncells in the bloodstream associated with metastatic spread. The median\nreduction was 83 percent within six to seven weeks of treatment.\n\n\"Two of the biggest challenges in treating triple-negative breast cancer are\nthe dormant cancer cells that spread through the bloodstream, and an immune\nsystem too exhausted to fight them. It's rare to see a treatment influence\nboth at the same time. After years of studying this disease, it's exciting to\nwitness this in a clinical setting. The circulating tumor cell clusters that\nseed new metastases are being suppressed, while the exhausted T cells needed\nto fight the cancer are recovering function and showing signs of immune\nmemory, which may translate to more durable responses. These changes in the\nblood are tracking with what we are seeing on the scans, which suggests our\nliquid biopsy approach may be capturing both the tumor's metastatic behavior\nand the immune system's response to treatment in real time. It gives us a\nremarkable window into the disease, and we look forward to building on these\nfindings as the trial progresses,\" said Dr. Sudha Rao, Chief Scientific\nOfficer, Kazia Therapeutics.\n\nThese early biological findings represent what may be a first-in-class effect\nand suggest that paxalisib's therapeutic effect may extend beyond cytoplasmic\nPI3K/mTOR inhibition. The rapid and consistent biological responses observed\nacross all evaluable patients support the hypothesis that paxalisib may exert\ndual influence by restoring immune function and reducing metastatic\ndissemination, addressing two of the greatest challenges in the treatment of\ntriple-negative breast cancer and fundamental drivers of cancer progression.\n\nEnrollment in the Company's ongoing Phase 1b study evaluating paxalisib in\ncombination with pembrolizumab (Keytruda(®)) and chemotherapy in advanced\nmetastatic TNBC is expected to be completed by July 2027, with interim\nclinical updates anticipated throughout 2026 and 2027.\n\nAbout Kazia Therapeutics\n\nKazia Therapeutics Limited (NASDAQ: KZIA\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4761405-1&h=2082862204&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fkazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html%23financial-modal&a=KZIA))\nis an oncology-focused drug development company, based in Sydney, Australia.\nThe Company's lead asset, paxalisib, is an investigational brain penetrant\ninhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat\nmultiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is\nor has been the subject of over 15 clinical trials. A completed Phase 2/3\nstudy in glioblastoma (GBM AGILE) was reported in 2024, and discussions are\nongoing for designing and executing a pivotal registrational study in pursuit\nof a standard approval. Other clinical trials involving paxalisib are ongoing\nin advanced breast cancer, brain metastases, diffuse midline gliomas, and\nprimary central nervous system lymphoma, with several of these trials having\nreported encouraging interim data. Paxalisib was granted Orphan Drug\nDesignation for glioblastoma by the U.S. Food and Drug Administration (FDA) in\nFebruary 2018, and Fast Track Designation (FTD) for glioblastoma in August\n2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid\ntumor brain metastases harboring PI3K pathway mutations in combination with\nradiation therapy.  Additionally, paxalisib was granted Rare Pediatric\nDisease Designation and Orphan Drug Designation by the FDA for diffuse\nintrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid\ntumors in June 2022 and July 2022, respectively. Kazia is also developing\nEVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec\nSE in April 2021. In addition to its clinical-stage programs, Kazia is\nadvancing NDL2, a potentially first-in-class intracellular PD-L1 protein\ndegrader program targeting a newly identified mechanism of immunotherapy\nresistance and metastatic progression, as well as MSETC, a potentially\nfirst-in-class SETDB1 inhibitor program intended to restore immune signaling\nin tumors that have become resistant to immunotherapy, including checkpoint\ninhibitors. Both programs are currently in preclinical development. For more\ninformation, please visit www.kaziatherapeutics.com or follow us on X\n@KaziaTx.\n\nForward-Looking Statements\n\nThis announcement may contain forward-looking statements, which can generally\nbe identified as such by the use of words such as \"may,\" \"will,\" \"estimate,\"\n\"future,\" \"forward,\" \"anticipate,\" \"expect,\" \"plan,\" \"believe,\" \"potential,\"\nor other similar words. Any statement describing Kazia's future plans,\nstrategies, intentions, expectations, objectives, goals or prospects, and\nother statements that are not historical facts, are also forward-looking\nstatements, including, but not limited to, statements regarding: the potential\nof paxalisib to provide clinical benefit, including objective responses, to\npatients with advanced triple-negative breast cancer; the preliminary and\ninterim nature of the clinical, translational and biomarker data described in\nthis announcement, and expectations regarding the durability of any observed\nresponses; the potential for future data to alter initial and preliminary\nresults from this early-stage clinical trial, which is based on a small number\nof patients and is not designed or powered to demonstrate statistical\nsignificance; the potential of paxalisib to restore anti-tumor immune function\nand reduce metastasis-associated circulating tumor cell clusters; the ability\nof translational and biomarker findings to predict clinical outcomes; the\ntiming of completion of enrollment in, and anticipated interim updates from,\nthe Company's ongoing Phase 1b study of paxalisib in combination with\npembrolizumab and chemotherapy in advanced metastatic TNBC; and the timing and\ncontent of future public disclosures regarding the Company's clinical programs\nand development strategy.\n\nSuch statements are based on Kazia's current expectations and projections\nabout future events and future trends affecting its business and are subject\nto certain risks and uncertainties that could cause actual results to differ\nmaterially from those anticipated in the forward-looking statements, including\nrisks and uncertainties associated with: the development of early-stage\ntherapeutic programs; the conduct of clinical trials, including the ability to\nenroll patients and achieve anticipated enrollment targets; the preliminary\nnature of preclinical data, which may not be predictive of clinical results in\nhumans; the preliminary nature of data from small, open-label clinical\nstudies, which are based on a small number of patients and may not be\npredictive of results in a larger patient population or in later-stage or\nfinal clinical trials; risks related to regulatory approvals; risks related to\nKazia's reliance on third-party collaborators and clinical trial sites; risks\nrelated to the Company's ability to obtain, maintain and protect its\nintellectual property, including the uncertainty of patent prosecution and the\npotential for third-party challenges; risks related to the impact of global\neconomic conditions; and risks related to Kazia's ability to maintain\ncompliance with the applicable NASDAQ continued listing requirements and\nstandards. These and other risks and uncertainties are described more fully in\nKazia's Annual Report on Form 20-F filed with the SEC, and in subsequent\nfilings with the United States Securities and Exchange Commission. Kazia\nundertakes no obligation to publicly update any forward-looking statement,\nwhether as a result of new information, future events, or otherwise, except as\nrequired under applicable law. You should not place undue reliance on these\nforward-looking statements, which apply only as of the date of this\nannouncement.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/apac/news-releases/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer-302862223.html\n\nSOURCE Kazia Therapeutics Limited\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1368769/Kazia-Logo.jpg?id=OA2917156\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPNAzMDNza","title":"Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer","author":"PR Newswire","ticker":"KZIA","created":"2026-08-27T20:01:00.638Z","tickers":["KZIA"],"exchange":"NASDAQ","article_body":"Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients\nTreated for Advanced Triple-Negative Breast Cancer\nPR Newswire\n\nSYDNEY, Aug. 28, 2026\n\nDurable Complete Metabolic Response Ongoing Since November 2025\n\nAll Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC\nClusters and Terminally Exhausted T cells, With Median Reductions of 83% and\n51% Respectively\n\nNo Treatment-Related Serious Adverse Events Observed\n\nSYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4761405-1&h=3234957468&u=https%3A%2F%2Fwww.kaziatherapeutics.com%2F&a=Kazia+Therapeutics+Limited) (NASDAQ:\nKZIA) (\"Kazia\" or the \"Company\"), an oncology-focused biotechnology company\ndeveloping therapies that selectively reprogram cancer biology, restore\nanti-tumor immunity and overcome treatment resistance, today announced new\ndata showing its lead asset, paxalisib, achieved a 100% clinical benefit rate\nin six evaluable patients with Stage IV triple-negative breast cancer (TNBC).\nFive of the six patients achieved an objective response – a measurable 30%\nor greater reduction in tumor burden after treatment – including one\ncomplete response and four partial responses, resulting in an objective\nresponse rate of 83 percent. The remaining patient achieved stable disease.\nImportantly, these results were achieved with the convenience of oral dosing\nand a favorable safety and tolerability profile, with no paxalisib-related\nserious adverse events and no grade 3 or higher hyperglycemia, stomatitis or\nmucositis, toxicities commonly associated with PI3K/mTOR pathway inhibition.\n\n\n\n\"Metastatic triple-negative breast cancer is one of the toughest cancers to\ntreat. Historically, only 12 percent\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4761405-1&h=21108310&u=https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fbreast%2Fbreast-cancer-types%2Ftriple-negative&a=12+percent) of\npatients are alive five years after diagnosis. Once a patient's disease\nprogresses on immunotherapy, options run out quickly,\" said Dr. John Friend,\nCEO, Kazia Therapeutics. \"Across the six evaluable patients treated, every one\nof them has benefited, and we haven't seen a single serious adverse event tied\nto paxalisib. We've also demonstrated meaningful improvements in terminally\nexhausted T cells and drastic reductions in circulating tumor cell (CTC)\nclusters, providing early evidence that paxalisib may be addressing biological\nmechanisms associated with treatment resistance and metastasis. These results\nstrengthen our confidence in this program as we continue enrollment in the\nPhase 1b trial.\"\n\nClinical responses were observed across a broad range of metastatic disease\nsites, including lung, liver, bone, lymph node and central nervous system\ntarget lesions, with responses emerging as early as approximately three months\npost-randomization. Most notably, a 44-year-old woman with Stage IV TNBC\nachieved a complete metabolic response and has had no evidence of disease\nsince November 2025. Her response has remained durable through the most recent\nassessment and has been accompanied by sustained and complete abolishment of\nCTC clusters and significant reduction in terminally exhausted CD8+ T cells,\nalongside overall improvement in markers of immune function.\n\nTranslational analyses demonstrated reductions in terminally exhausted CD8+ T\ncells across all six patients, with a median reduction of 51 percent within\napproximately three weeks of treatment. These cells represent a dysfunctional\npopulation of cytotoxic T cells that has lost its ability to recognize and\nkill cancer cells. Notably, total CD8+ T cell counts remained unchanged, which\nsuggests that paxalisib is not eliminating these exhausted cells or replacing\nthem with new ones. Instead, the existing cells appear to be regaining\nfunction. Blood-based simultaneous multi-modal protein, RNA and plasma\nprofiling supported this finding, demonstrating increases in immune cell\npopulations associated with anti-tumor activity, reductions in markers of\nimmune exhaustion and evidence of PI3K-AKT pathway target engagement. The\nmarker findings provide evidence of improved overall immune function across\nall patients.\n\nIn parallel with the immune changes, all six patients demonstrated reductions\nin circulating tumor cell clusters, which are aggressive groupings of tumor\ncells in the bloodstream associated with metastatic spread. The median\nreduction was 83 percent within six to seven weeks of treatment.\n\n\"Two of the biggest challenges in treating triple-negative breast cancer are\nthe dormant cancer cells that spread through the bloodstream, and an immune\nsystem too exhausted to fight them. It's rare to see a treatment influence\nboth at the same time. After years of studying this disease, it's exciting to\nwitness this in a clinical setting. The circulating tumor cell clusters that\nseed new metastases are being suppressed, while the exhausted T cells needed\nto fight the cancer are recovering function and showing signs of immune\nmemory, which may translate to more durable responses. These changes in the\nblood are tracking with what we are seeing on the scans, which suggests our\nliquid biopsy approach may be capturing both the tumor's metastatic behavior\nand the immune system's response to treatment in real time. It gives us a\nremarkable window into the disease, and we look forward to building on these\nfindings as the trial progresses,\" said Dr. Sudha Rao, Chief Scientific\nOfficer, Kazia Therapeutics.\n\nThese early biological findings represent what may be a first-in-class effect\nand suggest that paxalisib's therapeutic effect may extend beyond cytoplasmic\nPI3K/mTOR inhibition. The rapid and consistent biological responses observed\nacross all evaluable patients support the hypothesis that paxalisib may exert\ndual influence by restoring immune function and reducing metastatic\ndissemination, addressing two of the greatest challenges in the treatment of\ntriple-negative breast cancer and fundamental drivers of cancer progression.\n\nEnrollment in the Company's ongoing Phase 1b study evaluating paxalisib in\ncombination with pembrolizumab (Keytruda(®)) and chemotherapy in advanced\nmetastatic TNBC is expected to be completed by July 2027, with interim\nclinical updates anticipated throughout 2026 and 2027.\n\nAbout Kazia Therapeutics\n\nKazia Therapeutics Limited (NASDAQ: KZIA\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4761405-1&h=2082862204&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fkazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html%23financial-modal&a=KZIA))\nis an oncology-focused drug development company, based in Sydney, Australia.\nThe Company's lead asset, paxalisib, is an investigational brain penetrant\ninhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat\nmultiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is\nor has been the subject of over 15 clinical trials. A completed Phase 2/3\nstudy in glioblastoma (GBM AGILE) was reported in 2024, and discussions are\nongoing for designing and executing a pivotal registrational study in pursuit\nof a standard approval. Other clinical trials involving paxalisib are ongoing\nin advanced breast cancer, brain metastases, diffuse midline gliomas, and\nprimary central nervous system lymphoma, with several of these trials having\nreported encouraging interim data. Paxalisib was granted Orphan Drug\nDesignation for glioblastoma by the U.S. Food and Drug Administration (FDA) in\nFebruary 2018, and Fast Track Designation (FTD) for glioblastoma in August\n2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid\ntumor brain metastases harboring PI3K pathway mutations in combination with\nradiation therapy.  Additionally, paxalisib was granted Rare Pediatric\nDisease Designation and Orphan Drug Designation by the FDA for diffuse\nintrinsic pontine glioma in August 2020 and for atypical teratoid / rhabdoid\ntumors in June 2022 and July 2022, respectively. Kazia is also developing\nEVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec\nSE in April 2021. In addition to its clinical-stage programs, Kazia is\nadvancing NDL2, a potentially first-in-class intracellular PD-L1 protein\ndegrader program targeting a newly identified mechanism of immunotherapy\nresistance and metastatic progression, as well as MSETC, a potentially\nfirst-in-class SETDB1 inhibitor program intended to restore immune signaling\nin tumors that have become resistant to immunotherapy, including checkpoint\ninhibitors. Both programs are currently in preclinical development. For more\ninformation, please visit www.kaziatherapeutics.com or follow us on X\n@KaziaTx.\n\nForward-Looking Statements\n\nThis announcement may contain forward-looking statements, which can generally\nbe identified as such by the use of words such as \"may,\" \"will,\" \"estimate,\"\n\"future,\" \"forward,\" \"anticipate,\" \"expect,\" \"plan,\" \"believe,\" \"potential,\"\nor other similar words. Any statement describing Kazia's future plans,\nstrategies, intentions, expectations, objectives, goals or prospects, and\nother statements that are not historical facts, are also forward-looking\nstatements, including, but not limited to, statements regarding: the potential\nof paxalisib to provide clinical benefit, including objective responses, to\npatients with advanced triple-negative breast cancer; the preliminary and\ninterim nature of the clinical, translational and biomarker data described in\nthis announcement, and expectations regarding the durability of any observed\nresponses; the potential for future data to alter initial and preliminary\nresults from this early-stage clinical trial, which is based on a small number\nof patients and is not designed or powered to demonstrate statistical\nsignificance; the potential of paxalisib to restore anti-tumor immune function\nand reduce metastasis-associated circulating tumor cell clusters; the ability\nof translational and biomarker findings to predict clinical outcomes; the\ntiming of completion of enrollment in, and anticipated interim updates from,\nthe Company's ongoing Phase 1b study of paxalisib in combination with\npembrolizumab and chemotherapy in advanced metastatic TNBC; and the timing and\ncontent of future public disclosures regarding the Company's clinical programs\nand development strategy.\n\nSuch statements are based on Kazia's current expectations and projections\nabout future events and future trends affecting its business and are subject\nto certain risks and uncertainties that could cause actual results to differ\nmaterially from those anticipated in the forward-looking statements, including\nrisks and uncertainties associated with: the development of early-stage\ntherapeutic programs; the conduct of clinical trials, including the ability to\nenroll patients and achieve anticipated enrollment targets; the preliminary\nnature of preclinical data, which may not be predictive of clinical results in\nhumans; the preliminary nature of data from small, open-label clinical\nstudies, which are based on a small number of patients and may not be\npredictive of results in a larger patient population or in later-stage or\nfinal clinical trials; risks related to regulatory approvals; risks related to\nKazia's reliance on third-party collaborators and clinical trial sites; risks\nrelated to the Company's ability to obtain, maintain and protect its\nintellectual property, including the uncertainty of patent prosecution and the\npotential for third-party challenges; risks related to the impact of global\neconomic conditions; and risks related to Kazia's ability to maintain\ncompliance with the applicable NASDAQ continued listing requirements and\nstandards. These and other risks and uncertainties are described more fully in\nKazia's Annual Report on Form 20-F filed with the SEC, and in subsequent\nfilings with the United States Securities and Exchange Commission. Kazia\nundertakes no obligation to publicly update any forward-looking statement,\nwhether as a result of new information, future events, or otherwise, except as\nrequired under applicable law. You should not place undue reliance on these\nforward-looking statements, which apply only as of the date of this\nannouncement.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/apac/news-releases/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer-302862223.html\n\nSOURCE Kazia Therapeutics Limited\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1368769/Kazia-Logo.jpg?id=OA2917156\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-27T20:01:00.734833728Z","server_sent_at_ms":1787860860734},"received_at":"2026-08-27T20:01:01.083Z","source_url":null},"analysis":{"id":"118692","press_release_id":"129780","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Data based on a small sample size of six patients","Phase 1b results may not be predictive of success in larger, pivotal trials"],"eventType":"clinical_trial","narrative":"Kazia Therapeutics reported positive interim data from its Phase 1b study of paxalisib in Stage IV triple-negative breast cancer, showing a 100% clinical benefit rate and an 83% objective response rate across six evaluable patients. The treatment demonstrated a favorable safety profile with no serious adverse events and no high-grade hyperglycemia or stomatitis.\n\nBiomarker analyses indicated median reductions of 83% in metastasis-associated circulating tumor cell clusters and 51% in terminally exhausted T cells, suggesting the drug may address mechanisms of treatment resistance.\n\nCEO Dr. John Friend highlighted the durability of responses, noting one patient has been disease-free since November 2025, with enrollment in the ongoing study expected to complete by July 2027.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Paxalisib delivers 100% clinical benefit rate in aggressive TNBC with clean safety profile."},"keyFigures":{"drugName":"paxalisib","phaseOfTrial":"Phase 1b","customDimensions":{"patient_count":6,"median_ctc_reduction":"83%","clinical_benefit_rate":"100%","median_t_cell_reduction":"51%","objective_response_rate":"83%"}},"quotedText":"Across the six evaluable patients treated, every one of them has benefited, and we haven't seen a single serious adverse event tied to paxalisib.","namedEntities":{"people":[{"name":"Dr. John Friend","role":"CEO"},{"name":"Dr. Sudha Rao","role":"Chief Scientific Officer"}],"products":["paxalisib","pembrolizumab","Keytruda","EVT801","NDL2","MSETC"],"companies":[{"name":"Kazia Therapeutics Limited","ticker":"KZIA"},{"name":"Genentech","relationship":"licensor"},{"name":"Evotec SE","relationship":"licensor"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Paxalisib demonstrated a 100% clinical benefit rate and 83% objective response rate in six evaluable patients with Stage IV TNBC, a notoriously difficult-to-treat cancer. The favorable safety profile and strong biomarker data support the mechanism of action, though the small sample size (n=6) warrants caution until larger datasets are available."},"tickerRelevance":{"others":[],"primary":"KZIA"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"strong_early_stage_efficacy","sectorWeight":"biotech","sampleSizeConstraint":"n=6"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Kazia Therapeutics reported positive interim data from its Phase 1b study of paxalisib in Stage IV triple-negative breast cancer, showing a 100% clinical benefit rate and an 83% objective response rate across six evaluable patients. The treatment demonstrated a favorable safety profile with no serious adverse events and no high-grade hyperglycemia or stomatitis.\n\nBiomarker analyses indicated median reductions of 83% in metastasis-associated circulating tumor cell clusters and 51% in terminally exhausted T cells, suggesting the drug may address mechanisms of treatment resistance.\n\nCEO Dr. John Friend highlighted the durability of responses, noting one patient has been disease-free since November 2025, with enrollment in the ongoing study expected to complete by July 2027.","key_figures":{"drugName":"paxalisib","phaseOfTrial":"Phase 1b","customDimensions":{"patient_count":6,"median_ctc_reduction":"83%","clinical_benefit_rate":"100%","median_t_cell_reduction":"51%","objective_response_rate":"83%"}},"named_entities":{"people":[{"name":"Dr. John Friend","role":"CEO"},{"name":"Dr. Sudha Rao","role":"Chief Scientific Officer"}],"products":["paxalisib","pembrolizumab","Keytruda","EVT801","NDL2","MSETC"],"companies":[{"name":"Kazia Therapeutics Limited","ticker":"KZIA"},{"name":"Genentech","relationship":"licensor"},{"name":"Evotec SE","relationship":"licensor"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T20:04:00.879Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"small-cap","eventGravity":"strong_early_stage_efficacy","sectorWeight":"biotech","sampleSizeConstraint":"n=6"}},"durationMs":68235,"modelName":"glm-4.7"}}